Form 4: CRISPR CEO Kulkarni Granted 49,500 Stock Options

CRISPR Therapeutics CEO Samarth Kulkarni was granted 49,500 stock options with an exercise price of $67.74, vesting over 48 months.

Summary

• Samarth Kulkarni, Chief Executive Officer and Director of CRISPR Therapeutics AG, was granted 49,500 stock options.
• The stock options have an exercise price of $67.74 per common share.
• The grant date for these options was October 3, 2025.
• The options will vest in 48 equal monthly installments, with the first vesting date on November 3, 2025.
• The expiration date for these stock options is October 3, 2035.
• Following this transaction, Kulkarni beneficially owns 49,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a routine executive compensation event that aligns management's interests with shareholders, which is generally viewed positively. It does not, however, indicate any new operational or financial performance.

Positives

• The grant of stock options to CEO Samarth Kulkarni aligns his interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over 48 months promotes retention and sustained focus on strategic objectives.

Negatives

• No negative aspects are directly reported in this Form 4 filing, which primarily discloses an executive compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction. It solely reports an executive compensation event.

Industry Context

The grant of stock options is a standard practice in the biotechnology industry for executive compensation, aiming to attract, retain, and motivate key leadership by linking their financial incentives to the company's long-term stock performance. This aligns with common practices among peer companies in the gene-editing and pharmaceutical sectors.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, are a common component of remuneration for CEOs in the biotech sector, such as those at Vertex Pharmaceuticals, Regeneron Pharmaceuticals, or Moderna.
• The size and vesting schedule of the 49,500 options over 48 months are generally consistent with practices for executives in companies of similar market capitalization and stage of development, designed to incentivize long-term value creation. Specific comparable projects or results are not applicable to this type of filing.

Related Party Transactions

• This filing reports an executive compensation event (stock option grant) to the CEO, which is an insider transaction. It is not typically categorized as a 'related party transaction' in the context of specific disclosures for such dealings, but rather as a direct compensation component.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CEO's long-term financial interests with shareholder value creation.
• Employees: No direct impact on general employees is noted, though executive compensation practices can influence overall company culture and morale.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting November 3, 2025.
• Samarth Kulkarni may choose to exercise these options upon vesting, subject to the expiration date of October 3, 2035.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, Stock Options, Executive Compensation, Insider Transaction, Form 4, Biotechnology, Gene Editing